ArticleCureus2025
A Propensity-Matched Cohort Study Assessing Neuropathy in Patients With Leukocytoclastic Vasculitis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The objective of this study was to examine the potential relationship between leukocytoclastic vasculitis (LCV), a small-vessel vasculitis, and neuropathy. While LCV primarily affects the skin, its systemic involvement, including the development of neuropathy, has been increasingly recognized. This study aimed to assess whether LCV patients have a higher risk of developing neuropathy compared to a demographically matched control group. Materials and methods This retrospective cohort study utilized data from the TriNetX database (TriNetX, LLC, Cambridge, Massachusetts, USA). A total of 4,519 patients diagnosed with LCV were matched with 4,519 control patients based on demographic factors such as age, sex, and race to ensure comparable baseline characteristics between groups. Neuropathy in both groups was identified using the ICD-10-CM diagnostic code G62.9. Statistical analysis was performed to evaluate the relative risk of neuropathy in LCV patients compared to the control group. Results The analysis revealed that 5.4% of LCV patients were diagnosed with neuropathy, while 4.6% of the control group were affected. This difference was statistically significant, with a relative risk (RR) of 1.209, indicating that LCV patients have a 20.9% higher risk of developing neuropathy than controls (95% confidence interval (CI): 1.009-1.448, p = 0.0396). These findings suggest that LCV may contribute to the development of neuropathy. Conclusion This study provides evidence supporting the association between LCV and an increased risk of neuropathy. The findings highlight the potential for systemic neurological complications in patients with LCV, which may be attributed to vasculitic damage to the nerve blood supply. Despite the challenges in diagnosing LCV-associated neuropathy, the study underscores the importance of vigilant monitoring for neurological symptoms in LCV patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.